Phreesia, Inc.
NYSE:PHRMedical - Healthcare Information Services
+$0.08 today
- Market cap
- $760.99M
- Beta
- 0.88
- P/E (TTM)
- 62.6
- EPS (TTM)
- $0.15
Volume 0.86M
Average 1.97M
PHR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Phreesia, Inc.NYSE: PHR
Research & Development · Q1 FY2027 · quarter ended Apr 2026
Research & development declines year over year
Q1 FY2027 research & development of $28.33M fell 11.0% year over year, behind the -1.9% change in trailing-twelve-month research & development. Sequentially, it fell 8.4% from the prior quarter. Over 3 fiscal years it compounded at +10.0% a year.
Context
- Research & development amounted to 25.3% of revenue in FY2026, down 2.7 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -11.0% toward the trailing-twelve-month pace of -1.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 121.48M USD
- Year-over-year change
- +3.5%
- 4-year CAGR
- +23.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 121.48M | +3.5% |
| FY2025 | 2025-01-31 | 117.36M | +4.5% |
| FY2024 | 2024-01-31 | 112.35M | +23.1% |
| FY2023 | 2023-01-31 | 91.24M | +74.6% |
| FY2022 | 2022-01-31 | 52.27M | — |
Research & Development vs competitors
How PHR compares with its peers on the latest reported figures
- PHR's LTM Apr 2026 research & development of $117.98M is the 5th highest of the 11 companies compared; the peer median is $61.13M.
- Its year-over-year change of -1.9% is the 7th highest of 11, against a peer median of +0.8%.
- Research & development amounts to 23.8% of revenue for PHR, versus a peer median of 12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $320.12M | +4.5% | -5.9% | 12.7% | |
| LTM Mar 2026 | $229.1M | +8.2% | +2.9% | 34.0% | |
| LTM Sep 2026 | $160.31M | -11.5% | +11.1% | 59.6% | |
| LTM Mar 2026 | $120.06M | -3.1% | -5.4% | 15.2% | |
| LTM Apr 2026 | $117.98M | -1.9% | +10.0% | 23.8% | |
| LTM Mar 2026 | $89.67M | +1.0% | -5.8% | 7.3% | |
| LTM Mar 2026 | $32.6M | -8.9% | +15.8% | 11.5% | |
| LTM Sep 2026 | $20.08M | +0.6% | -0.0% | 7.6% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Jan 2026 | $19.24M | +36.6% | — | 23.0% | |
| LTM Mar 2026 | $8.14M | +5.5% | -20.0% | 8.2% | |
| Peer median (excluding PHR) | $61.13M | +0.8% | -5.4% | 12.1% | |
Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 213.23M | 280.91M | 356.3M | 419.81M | 480.59M |
| Cost of Revenue | 81.39M | 109.27M | 124.01M | 134.93M | 154.12M |
| Gross Profit | 131.85M | 171.64M | 232.29M | 284.88M | 326.47M |
| Gross Margin | 61.8% | 61.1% | 65.2% | 67.9% | 67.9% |
| Research & Development | 52.27M | 91.24M | 112.35M | 117.36M | 121.48M |
| Selling, General & Admin | 175.1M | 231.65M | 226.93M | 197.73M | 180.15M |
| Operating Expenses | 248.66M | 348.2M | 368.77M | 342.98M | 333.08M |
| Depreciation & Amortization | 24.52M | 28.77M | 30.54M | 27.89M | 31.45M |
| EBITDA | (92.3M) | (145.48M) | (102.95M) | (25.58M) | 29.47M |
| EBITDA Margin | -43.3% | -51.8% | -28.9% | -6.1% | 6.1% |
| Operating Income | (116.82M) | (176.55M) | (136.48M) | (58.1M) | (6.61M) |
| Operating Margin | -54.8% | -62.9% | -38.3% | -13.8% | -1.4% |
| Interest Income | 79K | 2.48M | 4.07M | 2.68M | 2.17M |
| Interest Expense | 1.16M | 1.41M | 1.85M | 2.35M | 6.95M |
| Other Income / Expenses | (1.16M) | 889K | 1.14M | 2.29M | (2.33M) |
| Income Before Tax | (117.98M) | (175.66M) | (135.34M) | (55.81M) | (8.94M) |
| Pre-Tax Margin | -55.3% | -62.5% | -38.0% | -13.3% | -1.9% |
| Income Tax Expense | 182K | 483K | 1.54M | 2.72M | (11.25M) |
| Net Income | (118.16M) | (176.15M) | (136.89M) | (58.53M) | 2.31M |
| Net Margin | -55.4% | -62.7% | -38.4% | -13.9% | 0.5% |
| EPS (Basic) | (2.37) | (3.36) | (2.51) | (1.02) | 0.04 |
| EPS (Diluted) | (2.37) | (3.36) | (2.51) | (1.02) | 0.04 |
| Weighted Avg Shares | 49.89M | 52.44M | 54.56M | 57.59M | 59.74M |
| Weighted Avg Shares (Diluted) | 49.89M | 52.44M | 54.56M | 57.59M | 61.49M |
Phreesia, Inc.
NYSE:PHR
Intrinsic Alpha fair value
Locked
Current Price
$12.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.